Literature DB >> 6197787

In vitro enhancement of bone marrow natural killer cells after incubation with thymopoietin32-36 (TP-5).

M Fiorilli, M C Sirianni, V Sorrentino, R Testi, F Aiuti.   

Abstract

Natural killer (NK) activity and interferon (IFN) production of spleen and bone-marrow lymphocytes were investigated in 8 to 10-wk-old C3HeB/FeJ/Cne mice, before and after in vitro exposure to the synthetic pentapeptide corresponding to positions 32-36 of the sequence of thymopoietin (TP-5). NK activity was studied against the 51Cr-radiolabelled Moloney virus-induced lymphoid cell line YAC 1, while IFN titres were determined by the inhibition of cytopathology of vesicular stomatitis virus on L929 cells, scored for CPE after 24 h from viral infection. A part of the lymphocytes from the spleen and bone marrow were incubated with different preselected doses (0.1, 1 and 10 micrograms/ml) of TP-5 for 1 h at 37 degrees C, and a part were left unincubated. At the end of the incubation time they were tested, without being washed, for NK activity and IFN production. TP-5 was able to significantly enhance (P less than 0.001 chi 2 test with Yate's correction) bone-marrow NK activity at a dose of 1 microgram/ml, while it was ineffective on spleen cells. A decrease of NK activity, seemingly due to a toxic effect, was observed both in bone-marrow and spleen lymphocytes, after incubation with a dose of 10 micrograms/ml. IFN production was not enhanced after exposure to TP-5. In all, our experiments suggest that TP-5 may enhance bone-marrow NK cells, perhaps by permitting the maturation of their precursors, as already known for T-cell-mediated cytotoxicity. Its effect is independent on IFN production and might be able to induce the rearrangement of certain surface specific receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6197787

Source DB:  PubMed          Journal:  Thymus        ISSN: 0165-6090


  2 in total

Review 1.  Thymic hormones--a clinical update.

Authors:  M B Sztein; A L Goldstein
Journal:  Springer Semin Immunopathol       Date:  1986

Review 2.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.